Multifaceted Role of Microbiota‐Derived Indole‐3‐Acetic Acid in Human Diseases and Its Potential Clinical Application
The FASEB Journal · 15.06.2025 · 39 (11)
DOI: 10.1096/fj.202500295r ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The FASEB Journal, online erschienen am 26.05.2025. Verfasst von Nargis Shaheen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Cell Biology, College of Medicine, The Ohio State University, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Indoleacetic Acids, Gastrointestinal Microbiome. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI), NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Indole‐3‐acetic acid (IAA) is recognized as a common plant growth hormone. It is also detectable in mammals, as it can be produced by gut microbiota in the gut. Current research works have shown that IAA is a multifaceted compound with significant consequences for several physiological and pathological processes. Higher levels of IAA occur in chronic kidney disease because decreased renal clearance contributes to cardiovascular and liver dysfunction. In contrast, IAA demonstrates protective effects by modulating oxidative stress, inflammation, and lipid metabolism in nonalcoholic fatty liver disease. IAA also shows potential therapeutic benefits in lung disorders such as acute lung injury, pulmonary fibrosis, and chronic obstructive pulmonary disease. Furthermore, IAA shows potential as an adjunct in cancer therapy, where it synergizes with chemotherapy regimens by endorsing oxidative stress and autophagy. Beyond cancer‐related applications and metabolic disorders, IAA's role in neuroinflammation, mainly in conditions such as sepsis‐associated encephalopathy and depression, underscores its potential as a therapeutic agent targeting the gut–brain axis. Furthermore, IAA is a potent oral hypoglycemic agent with mitigating effects on metabolic disorders associated with obesity and diabetes. This review provides an overview of the diverse roles of IAA in disease pathophysiology, its therapeutic promise, and the need for further research to better understand its mechanistic pathways. Understanding these complex effects could pave the way for novel microbiota‐based therapies to address a range of chronic diseases and improve patient outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Cell Biology, College of Medicine, The Ohio State University, Columbus, Ohio, USA.
- Davis Heart and Lung Research Institute, The Ohio State University, Columbus, Ohio, USA.
ORCID-Profile: Yutong Zhao, Jing Zhao
Förderung
- HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Shaheen, N., Miao, J., Xia, B., Zhao, Y., & Zhao, J. (2025). Multifaceted Role of Microbiota‐Derived Indole‐3‐Acetic Acid in Human Diseases and Its Potential Clinical Application. The FASEB Journal, 39(11). https://doi.org/10.1096/fj.202500295r
Vancouver
Shaheen N, Miao J, Xia B, Zhao Y, Zhao J. Multifaceted Role of Microbiota‐Derived Indole‐3‐Acetic Acid in Human Diseases and Its Potential Clinical Application. The FASEB Journal. 2025;39(11). doi:10.1096/fj.202500295r
BibTeX
@article{Shaheen2025,
author = {Shaheen, Nargis and Miao, Jiaxing and Xia, Boyu and Zhao, Yutong and Zhao, Jing},
title = {Multifaceted Role of Microbiota‐Derived Indole‐3‐Acetic Acid in Human Diseases and Its Potential Clinical Application},
journal = {The FASEB Journal},
year = {2025},
volume = {39},
number = {11},
doi = {10.1096/fj.202500295r}
}
EUVIMED